Valneva Responds to French Government's Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion

Company Overview - Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs [10][11] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines, including the world's first and only chikungunya vaccine, IXCHIQ® [11][12] Chikungunya Vaccine Response - Valneva is responding to a chikungunya outbreak in France's Island of La Réunion by providing 40,000 doses of its vaccine IXCHIQ® starting in early April 2025, with the option to supply more [1] - The vaccine supply is supported by the local public health agency and is prioritized for adults aged 65 and over with co-morbidities, as recommended by France's national public health agency [1][4] Outbreak Context - Chikungunya cases in La Réunion have surged, with 8,600 cases recorded and almost 3,000 new cases reported during the week of March 3 to 9, 2025 [2] - Local authorities have implemented a Level 4 emergency crisis management plan to contain the outbreak, and the CDC has issued a travel alert due to the risk of transmission to mainland France [2] Vaccine Approval and Expansion - IXCHIQ® is the first licensed chikungunya vaccine approved in the U.S., Europe, Canada, and the UK for individuals aged 18 and older, with a recent positive opinion from the EMA for a label extension to individuals aged 12 and older [3][5] - Valneva is focused on expanding the vaccine's label and access, including a partnership with CEPI supported by a $41.3 million grant to enhance access in Low- and Middle-Income Countries (LMICs) [5][6] International Partnerships - Valneva has signed an exclusive license agreement with the Serum Institute of India to supply the chikungunya vaccine in Asia at affordable prices for public health markets in LMICs [6][7] - This agreement complements a previous license signed with Instituto Butantan in Brazil for the development and marketing of a local chikungunya vaccine for distribution in Latin America and selected LMICs [7]